Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Faith Davies

Showing results (31-40 of 51) with videos related to

Pageof 6
Sort By:
The Oncologist|July 27, 2014
European perspective on multiple myeloma treatment strategies in 2014Heinz Ludwig, Pieter Sonneveld, Faith Davies, et al.
American Journal of Hematology|April 7, 2017
Clinical characteristics and prognostic factors in multiple myeloma patients with light chain deposition diseaseMeera Mohan, Amy Buros, Pankaj Mathur, et al.
Blood|October 18, 2002
Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myelomaPaul G Richardson, Robert L Schlossman, Edie Weller, et al.
Haematologica|April 29, 2021
Carfilzomib or bortezomib in combination with cyclophosphamide and dexamethasone followed by carfilzomib maintenance for patients with multiple myeloma after one prior therapy: results from a multicenter, phase II, randomized, controlled trial (MUK<i>five</i>)Kwee L Yong, Samantha Hinsley, Holger W Auner, et al.
Blood Cancer Journal|June 20, 2020
Genomic analysis of primary plasma cell leukemia reveals complex structural alterations and high-risk mutational patternsCarolina Schinke, Eileen M Boyle, Cody Ashby, et al.
The Oncologist|May 11, 2012
European perspective on multiple myeloma treatment strategies: update following recent congressesHeinz Ludwig, Hervé Avet-Loiseau, Joan Bladé, et al.
Biorxiv : the Preprint Server for Biology|November 28, 2024
Mutagenic impact and evolutionary influence of radiotherapy in hematologic malignanciesBenjamin Diamond, Dhanvantri Chahar, Michael D Jain, et al.
Future Oncology (London, England)|July 14, 2026
Effectiveness of daratumumab plus bortezomib, lenalidomide, and dexamethasone (DVRd) versus VRd for transplant-eligible newly diagnosed multiple myelomaCarlyn Rose Tan, Lucio Gordan, Joshua Richter, et al.
Annals of Hematology|May 10, 2021
Real-world comparative effectiveness of triplets containing bortezomib (B), carfilzomib (C), daratumumab (D), or ixazomib (I) in relapsed/refractory multiple myeloma (RRMM) in the USFaith Davies, Robert Rifkin, Caitlin Costello, et al.
Blood|August 16, 2011
Personalized therapy in multiple myeloma according to patient age and vulnerability: a report of the European Myeloma Network (EMN)Antonio Palumbo, Sara Bringhen, Heinz Ludwig, et al.
Pageof 6

Showing results (31-40 of 51) with videos related to

Sort By:
Pageof 6
The Oncologist|July 27, 2014
European perspective on multiple myeloma treatment strategies in 2014Heinz Ludwig, Pieter Sonneveld, Faith Davies, et al.
American Journal of Hematology|April 7, 2017
Clinical characteristics and prognostic factors in multiple myeloma patients with light chain deposition diseaseMeera Mohan, Amy Buros, Pankaj Mathur, et al.
Blood|October 18, 2002
Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myelomaPaul G Richardson, Robert L Schlossman, Edie Weller, et al.
Haematologica|April 29, 2021
Carfilzomib or bortezomib in combination with cyclophosphamide and dexamethasone followed by carfilzomib maintenance for patients with multiple myeloma after one prior therapy: results from a multicenter, phase II, randomized, controlled trial (MUK<i>five</i>)Kwee L Yong, Samantha Hinsley, Holger W Auner, et al.
Blood Cancer Journal|June 20, 2020
Genomic analysis of primary plasma cell leukemia reveals complex structural alterations and high-risk mutational patternsCarolina Schinke, Eileen M Boyle, Cody Ashby, et al.
The Oncologist|May 11, 2012
European perspective on multiple myeloma treatment strategies: update following recent congressesHeinz Ludwig, Hervé Avet-Loiseau, Joan Bladé, et al.
Biorxiv : the Preprint Server for Biology|November 28, 2024
Mutagenic impact and evolutionary influence of radiotherapy in hematologic malignanciesBenjamin Diamond, Dhanvantri Chahar, Michael D Jain, et al.
Future Oncology (London, England)|July 14, 2026
Effectiveness of daratumumab plus bortezomib, lenalidomide, and dexamethasone (DVRd) versus VRd for transplant-eligible newly diagnosed multiple myelomaCarlyn Rose Tan, Lucio Gordan, Joshua Richter, et al.
Annals of Hematology|May 10, 2021
Real-world comparative effectiveness of triplets containing bortezomib (B), carfilzomib (C), daratumumab (D), or ixazomib (I) in relapsed/refractory multiple myeloma (RRMM) in the USFaith Davies, Robert Rifkin, Caitlin Costello, et al.
Blood|August 16, 2011
Personalized therapy in multiple myeloma according to patient age and vulnerability: a report of the European Myeloma Network (EMN)Antonio Palumbo, Sara Bringhen, Heinz Ludwig, et al.
Pageof 6